FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00066638 |
Recruitment Status :
Completed
First Posted : August 7, 2003
Last Update Posted : March 17, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
DS Stage II Plasma Cell Myeloma DS Stage III Plasma Cell Myeloma Refractory Plasma Cell Myeloma | Drug: Romidepsin Other: Laboratory Biomarker Analysis | Phase 2 |
PRIMARY OBJECTIVES:
I. To evaluate the safety and efficacy of depsipeptide in patients with refractory or relapsed multiple myeloma (MM).
OUTLINE: This is a multicenter study.
Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a stable plateau (stable paraprotein levels or urine protein excretion over 3 consecutive determinations at least 4 weeks apart) may receive maintenance therapy comprising FR901228 IV on days 1 and 15, with courses repeating every 28 days.
PROJECTED ACCRUAL: A total of 21-50 patients will be accrued for this study within 5-12.5 months.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2 Study of Depsipeptide in Relapsed/Refractory Multiple Myeloma |
Study Start Date : | June 2003 |
Actual Primary Completion Date : | May 2007 |
Actual Study Completion Date : | March 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (romidepsin)
Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a stable plateau (stable paraprotein levels or urine protein excretion over 3 consecutive determinations at least 4 weeks apart) may receive maintenance therapy comprising FR901228 IV on days 1 and 15, with courses repeating every 28 days.
|
Drug: Romidepsin
Given IV Other: Laboratory Biomarker Analysis Correlative studies |
- Response rate (complete response [CR] or partial response [PR]) [ Time Frame: Up to 8 years ]
- Event free survival [ Time Frame: Up to 8 years ]
- Gene array parameters [ Time Frame: Up to 8 years ]This analysis will be descriptive and will compare patterns of gene and phenotype expression pre and post therapy.
- Immunochemistry parameters [ Time Frame: Up to 8 years ]This analysis will be descriptive and will compare patterns of gene and phenotype expression pre and post therapy.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed stage IIa or IIIa multiple myeloma
- Patient has progressive disease and has had 1, 2, 3, or 4 prior lines of therapy
- Bilirubin < 2.0 mg/dL
- SGOT/SGPT =< 2.5 X institutional upper limit of normal
- Serum creatinine =< 1.5 mg/dl OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- Karnofsky Performance Status equal or greater than 70%; KPS 60% will be allowed if reduced KPS is due to advanced skeletal disease
- Measurable disease as defined by serum M protein >= 1.0 gm/dl measured by serum protein electrophoresis or free light chain measurement, or quantitative immunoglobulins and/or urinary M protein excretion >= 200 mg/24 hrs
- Ejection fraction >= 50% and normal baseline EKG tracing
- No known central nervous system abnormality including neoplastic, vascular, inflammatory, degenerative or epilepsy
- Life expectancy of greater than 12 weeks
- Leukocytes >= 3,000/uL
- Absolute neutrophil count >= 1,500/uL
- Platelets >= 100,000/uL
-
Patients in whom cytopenias are considered to be due to myeloma marrow infiltration will be allowed as long as they meet the following criteria:
- Bone marrow biopsy displaying >= normal cellularity for age and >= 50% involvement by myeloma
- ANC > 1,000 and platelets > 50,000
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign written informed consent
Exclusion Criteria:
- Administration of chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to enrollment or unresolved adverse events due to agents administered more than 4 weeks earlier
- Prior treatment with a histone deacetylase inhibitor
- Patients may not be receiving any other investigational agent
- History of second cancer (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free >= 5 years)
- Non secretory disease or plasma cell leukemia (> 2000 circulating plasma cells/uL)
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to depsipeptide
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients with left ventricular hypertrophy or history of arrhythmias including atrial fibrillation, myocardial infarction or congestive heart failure; patients may not be taking hydrochlorothiazides
- Patients that are pregnant or lactating will be excluded from this trial
- Known HIV positivity; patients infected with the HIV virus will be excluded from this trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00066638
United States, New York | |
Montefiore Medical Center - Moses Campus | |
Bronx, New York, United States, 10467-2490 |
Principal Investigator: | Ruben Niesvizky-Iszaevich | Montefiore Medical Center - Moses Campus |
Responsible Party: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00066638 |
Other Study ID Numbers: |
NCI-2012-03005 NCI-2012-03005 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) NCI-5996 0403-765 ( Other Identifier: Montefiore Medical Center - Moses Campus ) 5996 ( Other Identifier: CTEP ) N01CM62204 ( U.S. NIH Grant/Contract ) P30CA013330 ( U.S. NIH Grant/Contract ) |
First Posted: | August 7, 2003 Key Record Dates |
Last Update Posted: | March 17, 2015 |
Last Verified: | December 2012 |
Multiple Myeloma Romidepsin Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias |
Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Antibiotics, Antineoplastic Antineoplastic Agents |